BioInno Bioscience Co., Ltd. (BioInno) is an international biopharmaceutical CDMO with serum-free cell culture media development and manufacturing. We are committed to providing global biopharmaceutical companies with one-stop CDMO services including cell line development, process development, clinical material manufacturing, IND application filing and GMP manufacturing of BLA and marketed products, with a service platform for customized development and manufacturing of cell culture media as well as quality auditing and consultation.
Our founding team has gathered world-class experts with extensive experience to allow the company to have world-class CDMO operation capability since the beginning of our establishment. Xiaojian (David) Zhao, PhD, is an internationally renowned scientist and biopharmaceutical expert in the field of cell culture and cell culture media. He has developed dozens of mainstream high-end serum-free media and feeds that are currently still marketed globally and has accumulated decades of experience in biopharmaceutical R&D and manufacturing. Our COO, Scott M Wheelwright, PhD, is one of the founders of Innovent Biologics (Suzhou) Co., Ltd., a global quality expert and a biopharmaceutical expert. The R&D and manufacturing base built by his team has a world-class quality system that meets the GMP standards of the FDA, EMEA and Chinese NMPA.
We have established our production and R&D base in Taicang near Suzhou, with our R&D center in Suzhou biopharmaceutical Industrial Park (bioBAY). Our Taicang manufacturing and R&D base covers an area of more than 12,000 square meters (≈120,000 square feet) and has capacity for media manufacturing, cell culture and microbial protein therapeutics manufacturing, plasmid manufacturing, virus manufacturing and aseptic drug product (vials and prefilled syringe) manufacturing. With multiple manufacturing lines and sufficient manufacturing capacity, we can efficiently provide global customers with low-cost, customized, and diversified products and services. At the same time, our R&D centers in Taicang and Suzhou enable us to have strong R&D capabilities to provide customized R&D services to match the needs of diverse customers.
In the future, BioInno will continue to reduce project costs through efficient manufacturing capacity layout and deeper industrial supply chain integration and practice the company's mission to “Enable Patients to Use Advanced Biopharmaceuticals at an Affordable Price”.